- Home
- ANAB vs EDN Comparison
ANAB vs EDN Comparison
Compare ANAB & EDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- EDN
- Stock Information
- Founded
- ANAB 2005
- EDN 1992
- Country
- ANAB United States
- EDN Argentina
- Employees
- ANAB N/A
- EDN N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- EDN Electric Utilities: Central
- Sector
- ANAB Health Care
- EDN Utilities
- Exchange
- ANAB Nasdaq
- EDN Nasdaq
- Market Cap
- ANAB 681.9M
- EDN 973.3M
- IPO Year
- ANAB 2017
- EDN 2007
- Fundamental
- Price
- ANAB $35.18
- EDN $23.18
- Analyst Decision
- ANAB Buy
- EDN
- Analyst Count
- ANAB 10
- EDN 0
- Target Price
- ANAB $51.10
- EDN N/A
- AVG Volume (30 Days)
- ANAB 279.7K
- EDN 103.0K
- Earning Date
- ANAB 10-31-2024
- EDN 10-29-2024
- Dividend Yield
- ANAB N/A
- EDN N/A
- EPS Growth
- ANAB N/A
- EDN N/A
- EPS
- ANAB N/A
- EDN 0.28
- Revenue
- ANAB $30,473,000.00
- EDN $880,068,817.00
- Revenue This Year
- ANAB $90.79
- EDN $144.81
- Revenue Next Year
- ANAB N/A
- EDN $84.99
- P/E Ratio
- ANAB N/A
- EDN $4.98
- Revenue Growth
- ANAB 135.59
- EDN N/A
- 52 Week Low
- ANAB $13.36
- EDN $10.06
- 52 Week High
- ANAB $41.31
- EDN $25.71
- Technical
- Relative Strength Index (RSI)
- ANAB 53.02
- EDN 56.38
- Support Level
- ANAB $32.46
- EDN $22.57
- Resistance Level
- ANAB $35.77
- EDN $24.23
- Average True Range (ATR)
- ANAB 1.70
- EDN 0.99
- MACD
- ANAB 0.20
- EDN -0.12
- Stochastic Oscillator
- ANAB 87.38
- EDN 63.29
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.